Multimodal stratification of predictive biomarkers in head and neck cancers: A focus on cytokine-based immunotherapy
Explore our recent poster presentation, which discusses the challenge of identifying predictive biomarkers for cytokine-based immunotherapy in head and neck cancers due to the complexity of biological systems and cancer pathophysiology. It highlights the importance of understanding how drugs interact with different biomarkers and tissues spatially to improve trial success rates, reduce costs, and accelerate completion times.
By analyzing spatial and temporal changes in tumor cells and their microenvironment, you can uncover resistance mechanisms, leading to the design of more effective combination therapies. The Aliri solution offers enhanced tumor profiling through spatial analysis, integration of heterogenous data types, and predictive analysis, ultimately identify robust biomarker signatures for improved immunotherapy outcomes.
Download our poster to gain insights into the unique biomarker signatures correlated with therapy response.
Keeping an eye on molecular imaging: drug efficacy & toxicity in ophthalmology
Discover how Mass Spectrometry Imaging (MSI) is revolutionizing preclinical studies by offering quick and accurate assessments of ocular treatments’ efficacy and safety.
With MSI, track the bio-distribution of drugs and metabolites while pinpointing biomarkers for efficacy or toxicity. Gain valuable insights into ocular drug distribution and biomarker modulation with Aliri’s advanced MSI technology.
Download our application note to dive deeper into our MSI technology and its applications in ocular diseases.
Coproporphyrin-I and Coproporphyrin-III
Aliri Bioanalysis presents a newly validated non-proprietary biomarker assay (NPA) for the quantitation of Coproporphyrin I and Coproporphyrin III in human plasma. This assay offers significant advancements in biomarker analysis, applicable across diagnostics, pharmaceutical research, and patient care.
By monitoring these biomarkers, particularly in early clinical development, companies can assess OATP1B1 inhibition, potentially avoiding the need for dedicated clinical drug-drug interaction studies, saving both time and money.
Learn more about the benefits of our NPA for Coproporphyrin I and Coproporphyrin III.
Mercapturate pathway metabolites of sotorasib, a covalent inhibitor of KRAS G12C , are associated with renal toxicity in the Sprague Dawley rat
Sotorasib is a first-in class KRAS G12C covalent inhibitor in clinical development for the treatment of tumors with
the KRAS p.G12C mutation. In the nonclinical toxicology studies of sotorasib, the kidney was identified as a
target organ of toxicity in the rat but not the dog. Renal toxicity was characterized by degeneration and necrosis
of the proximal tubular epithelium localized to the outer stripe of the outer medulla (OSOM), which suggested
that renal metabolism was involved. Here, we describe an in vivo mechanistic rat study designed to investigate
the time course of the renal toxicity and sotorasib metabolites. Renal toxicity was dose- and time-dependent,
restricted to the OSOM, and the morphologic features progressed from vacuolation and necrosis to regeneration
of tubular epithelium. The renal toxicity correlated with increases in renal biomarkers of tubular injury.
Using mass spectrometry and matrix-assisted laser desorption/ionization, a strong temporal and spatial associ –
ation between renal toxicity and mercapturate pathway metabolites was observed. The rat is reported to be
particularly susceptible to the formation of nephrotoxic metabolites via this pathway. Taken together, the data
presented here and the literature support the hypothesis that sotorasib-related renal toxicity is mediated by a
toxic metabolite derived from the mercapturate and B-lyase pathway. Our understanding of the etiology of the rat
specific renal toxicity informs the translational risk assessment for patients.
A New Safety Concern for Glaucoma Treatment Demonstrated by Mass Spectrometry Imaging of Benzalkonium Chloride Distribution in the Eye, an Experimental Study in Rabbits
We investigated in a rabbit model, the eye distribution of topically instilled benzalkonium (BAK) chloride a commonly used preservative in eye drops using mass spectrometry imaging. Three groups of three New Zealand rabbits each were used: a control one without instillation, one receiving 0.01%BAK twice a day for 5 months and one with 0.2%BAK one drop a day for 1 month. After sacrifice, eyes were embedded and frozen in tragacanth gum. Serial cryosections were alternately deposited on glass slides for histological (hematoxylin-eosin staining) and immunohistological controls (CD45, RLA-DR and vimentin
for inflammatory cell infiltration as well as vimentin for Mu¨ller glial cell activation) and ITO or stainless steel plates for MSI experiments using Matrix-assisted laser desorption ionization time-of-flight. The MSI results were confirmed by a roundrobin study on several adjacent sections conducted in two different laboratories using different sample preparation methods, mass spectrometers and data analysis softwares. BAK was shown to penetrate healthy eyes even after a short
duration and was not only detected on the ocular surface structures, but also in deeper tissues, especially in sensitive areas involved in glaucoma pathophysiology, such as the trabecular meshwork and the optic nerve areas, as confirmed by images with histological stainings. CD45-, RLA-DR- and vimentin-positive cells increased in treated eyes. Vimentin was found only in the inner layer of retina in normal eyes and increased in all retinal layers in treated eyes, confirming an activation response to a cell stress. This ocular toxicological study confirms the presence of BAK preservative in ocular surface structures as well
as in deeper structures involved in glaucoma disease. The inflammatory cell infiltration and Mu¨ller glial cell activation confirmed the deleterious effect of BAK. Although these results were obtained in animals, they highlight the importance of the safety-first principle for the treatment of glaucoma patients.
On-demand webinar: Importing and exporting biological samples
Importing and exporting biological samples to and from a US bioanalytical lab requires the US government’s oversight to prevent the transportation of exotic diseases and the supplying of illegal markets. Pharma companies and bioanalytical partners must proactively work together to secure the correct import or export licenses or permits prior to shipment to ensure international samples arrive intact and on time. In this webcast, learn more about how the process is navigated to help you successfully plan your study’s timeline and avoid compromising your samples in transit.
On-demand webinar: Visualize immune cells abundance in tumors to determine therapeutic efficacy
The significance of spatial immune signatures lies in the determination of immune cell types, activation status, spatial distribution, and intricate interactions within tissues. These unique signatures play a pivotal role in various fields, particularly cancer, immunology, and autoimmune diseases, where the effectiveness of treatments is intricately linked to the immune response within tissues. By incorporating spatial immune signatures into phase II trials, early insights into treatment responses can be gained, offering a reflection of clinical outcomes. This approach expedites decision-making regarding drug candidate progression in later phases of clinical development, ultimately saving valuable time and resources for your program.
Watch this on-demand presentation led by industry expert Corinne Ramos, Director of R&D, Aliri Bioanalysis, as we unveil our clinical trial findings alongside the innovative technologies and state-of-the-art computational tools that have revolutionized our capacity to observe and decipher spatial immune signatures.
What you’ll learn:
- Understand the significance of spatial immune signatures in assessing early treatment efficacy.
- Explore our patient-centric approach, which includes baseline profiling and ongoing monitoring.
- Gain insights into leveraging these techniques for drug development.
- Discover how this approach can save your program valuable time and resources.
Multimodal stratification of predictive biomarker in lung cancer: A focus on immune checkpoint inhibitor
Dive into the complex landscape of immune checkpoint inhibitors (ICIs) in lung cancer in our poster presentation.
As the use of immunotherapy in early-stage non-small cell lung cancer (NSCLC) remains a challenge, we offer a spatially-informed approach to identify useful biomarkers. By using spatial biomarker assays, and analysis involving spatial transcriptomics and proteomics, we reveal the cell-to-cell interactions in the tumor microenvironment.
Download our poster to explore our findings and gain insights into the suitability of ICIs for personalized therapy
Spatial distribution of B cells and lymphocyte clusters for the treatment of non-small cell lung cancer
Explore the spatial organization of tertiary lymphoid structures (TLS) in non-small cell lung cancer (NSCLC) and its impact on ant-PD-1 treatment response in our poster presentation.
Using high-plex imaging mass cytometry staining, we investigated the relationship between TLS spatial organization, the tumor microenvironment, and patient response to therapy. We leveraged deep learning for cell segmentation and characterization to identify that the presence of tumor-associated TLS correlates with a positive response to ant-PD-1 therapy.
Download our poster to dive into this spatial distribution insight and its potential impact on immunotherapies.
Highly sensitive analysis using EVOSEP-LC-MS/MS assay for targeted PD-L1 and PD-1 expression level for predicting response to immune checkpoint inhibitors
Explore our recent poster presentation, which dives into a highly sensitive analysis using an EVOSEP-LC-MS/MS assay, with a focus on targeted PD-L1 and PD-1 expression levels to predict responses to immune checkpoint inhibitors (ICIs).
We address the limitations of traditional PD-L1 and PD-1 immunoassays and their uncertain clinical value across tumor types. Through analysis of our robust method against routine immunoassays, and use of Overall Response Rate (ORR), we offer a new perspective on the predictive power of biomarkers for non-small cell lung cancer (NSCLC) therapy.
Download our poster to discover the potential of this innovative approach.